Call Us: 1.800.873.5297

By

Pharmaceutical Companies Slant Research on Defective Drugs

In attempting to assess the risks of any potentially defective drugs, diligent doctors rely not only on the drug companies or the FDA to communicate risks, but perform independent research, looking through scientific literature in their off hours to discover whether the drugs they prescribe are more helpful or harmful to their patients. Of course, some doctors don’t research potentially dangerous drugs, but even when doctors research the drugs they prescribe, drug companies strive to flood the literature with reports favorable to their drugs.

If you were injured by a defective drug, it is possible that drug companies promoted that drug’s effectiveness and concealed its potential dangers. When this occurs, you may be eligible to receive additional compensation for your injuries caused by defective drugs. To learn whether you may be able to receive compensation, schedule a defective drug injury consultation with the drug injury attorneys at Schlichter, Bogard & Denton today.

Funding Affects Results of Dangerous Drug Studies

The preferred view of science is that it objectively evaluates drugs during rigorous trials to prove whether a drug is truly safe and effective or is defective and dangerous. The truth is, though, that scientists work in a context where their work is often anything but objective. Studies on literature have shown that scientists’ conclusions often depend on who is funding the study. It is not quite a pay-for-play system, but if a company funds a study, it is more likely that the company’s product will be reported in a favorable light. Since pharmaceutical companies pay for the majority of studies conducted on their drugs, these studies may tend to show drugs, even defective drugs, in a more favorable light.

Favorable Drug Studies More Likely to Be Published

Over half of all studies conducted during the FDA approval process are never published. Analysis shows that three main factors determine which studies are published and which are not:

  • Studies designated as “pivotal” by FDA are more likely to be published
  • Studies with larger sample sizes are more likely to be published
  • Studies with statistically significant results are more likely to be published

This means that numerous studies showing a potentially dangerous drug has little to no value over existing treatments or placebo may sit unpublished and unknown, so that when a doctor looks at the medical journals, all that will show up are studies showing that it is valuable, making the doctor more likely to prescribe a new, potentially defective drug.

Pharmaceutical Companies Ghost Write Articles

Even when no research is available to support positive results or squelch dangers of a defective drug, pharmaceutical companies get articles published in support of their products by using ghost writers. In one such scheme, Wyeth, soon to be a subsidiary of Pfizer (manufacturer of Dilantinpromoted its drugs by:

  • Inventing a title for an article and deciding a medical journal where they wanted it published
  • Drafting an outline for the article to be written by a ghostwriter
  • Recruiting an academic author to put his name on the article
  • Submitting the article to the medical journal, which published it

Since the identity of the actual author was concealed, and the article’s connection to drug manufacturers was not revealed, the article was read by doctors and scientists as genuine scholarly research.

Experienced Lawyers Can Expose Slanted Drug Research

If you are seeking compensation for a defective drug injury, whether you receive compensation or not may depend on showing a jury the type of manipulation performed to make a drug seem safe and effective. To do this, you need a lawyer who knows the legal, medical, and scientific issues at stake. You need a lawyer with experience and recognized leadership in pharmaceutical litigation.

The pharmaceutical litigation lawyers at Schlichter, Bogard & Denton have obtained millions for clients who suffered defective drug injuries. And our leadership in this field has been recognized by our peers, who have nominated our lawyers to membership in the small, elite Plaintiffs’ Steering Committees (PSC’s) that are responsible for managing the conduct of complex, multidistrict litigation.

If you want an experienced and nationally-recognized leader in the field of pharmaceutical litigation to take your case, contact us to schedule a free, no-obligation defective drug injury consultation with a lawyer at Schlichter, Bogard & Denton today.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.